Navigation Links
FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
Date:6/15/2009

BOSTON, June 15 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.

The results of this study will be presented by Dr. David Elmaleh, Director of Contrast Media Chemistry at the Massachusetts General Hospital and Associate Professor at Harvard Medical School, at the "New Tracers, New Agents and New Stressors" scientific session on Tuesday, June 16, 2009, from 1:15 p.m. - 1:30 p.m. (EDT).

BFPET is 18-F labeled tetraphenylphosphonium compound, designed to assess mitochondrial damage and myocardial perfusion. Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD) with more than 9 million Americans undergoing the test annually.

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries. www.fluoropharma.com

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE FluoroPharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
2. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
3. Michael Simmons, DMD presented a poster at the American Academy of Dental Sleep Medicine Meeting
4. WebMD to Present at Jefferies 3rd Annual Healthcare Conference
5. Alexzas Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
6. First-Ever Standardized Scales to Measure the Skins Aging Process Are Presented at THE Aesthetic Show
7. Isis Pharmaceuticals to Present at Jefferies 3rd Annual Healthcare Conference
8. IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference
9. NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies
10. Kensey Nash to Present at the Jefferies 3rd Annual Healthcare Conference
11. Latest trinational report presents most complete picture of North American industrial pollution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Watsonville, California (PRWEB) , ... May 04, 2016 ... ... powerful formulation of foundational nutrients that supports cellular and metabolic health. This synergistic ... and 400 mg free-form curcumin, along with 150 mg of reduced glutathione and ...
(Date:5/4/2016)... ... , ... Natalie Jill is a well respected lifestyle mentor and ... launch of her new book: Natalie Jill’s 7 Day Jump Start: Unprocess Your Diet ... start a new healthy lifestyle featuring simple recipes using MitoXcell’s raw cacao formula. ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco Products has announced the ... dual-light flashlights in models NSP-9842XL and NSR-9844XL . , First previewed at ... uses 2 included CR-123 batteries to produce up to 650 lumens in a ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... ankles, and elbows. Engineered with athletes in mind, OMNIFORCE offers high-performance, less ... ineffective circular knitting, common in the industry) produces premium flat-knit construction with ...
(Date:5/4/2016)... KS (PRWEB) , ... May 04, 2016 , ... ... Transtem™ Patient 2016, a powerful cellular therapy software application that helps blood ... treatments to patients. , Since Transtem’s initial launch, Mediware has continued to enhance ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Research and Markets has ... Myeloma Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Multiple ... Myeloma market valuations and forecast, Multiple Myeloma ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute lymphocytic Leukemia Market and ... their offering.       (Logo: ... Lymphocytic Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Lymphocytic Leukemia epidemiology, ...
(Date:5/3/2016)... acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and ... ... ... ... ...
Breaking Medicine Technology: